Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

Loricera, J.; Blanco, Ricardo; Hernández, José L.; Castañeda, Santos; Mera, Antonio; Pérez‐Pampín, Eva; Peirό, E.; Humbría, Alicia; Calvo‐Alén, Jaime; Aurrecoechea, Elena; Narváez, Javier; Sánchez-Andrade, A; Vela, Paloma; Díez, E.; Mata, Cristina; Lluch, Pau; Moll, Concepción; Hernández, Iñigo; Calvo-Río, V.; Sanjuán, Francisco Miguel Ortíz; González-Vela, Carmen; Pina, Trinitario; González-Gay, Miguel Á.

doi:10.1016/j.semarthrit.2014.12.005

Cited by 117 publications

(53 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seven similar cases of pure PMR treated by TCZ have previously been reported 7,8,9,10 , while a substantially higher number of patients with GCA have received this biological agent 4,5 . In PMR cases, TCZ was given as a monthly 8 mg/kg infusion with a clinical response observed within 4 to 12 weeks.…”

Section: To the Editormentioning

confidence: 63%

“…Mounting evidence suggests that IL-6 plays a major role in sustaining disease activity in PMR and its related disorder, GCA. Tocilizumab led to favorable results in GCA-specific symptoms and also in associated PMR 4,5 .…”

Section: To the Editormentioning

confidence: 99%

“…Data suggest that interleukin 6 (IL-6) contributes to the inflammatory process of PMR 2 : Increased serum levels of IL-6 have been described in PMR and correlate with disease activity 3 ; the risk of recurrence/relapse of PMR is associated with persistent elevated IL-6 serum levels as well as with a genetic polymorphism of the IL-6 promoter gene 3 ; and reports described the efficacy of tocilizumab (TCZ), an anti-IL-6 receptor agent, in the treatment of giant cell arteritis (GCA) 4,5 . The clinical value of TCZ in isolated PMR is less well described.…”

Section: To the Editormentioning

confidence: 99%

See 2 more Smart Citations

Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study

Toussirot

Martin

Soubrier³

et al. 2016

J Rheumatol

View full text Add to dashboard Cite

Section: To the Editormentioning

confidence: 63%

Section: To the Editormentioning

confidence: 99%

Section: To the Editormentioning

confidence: 99%

See 1 more Smart Citation

Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study

Toussirot

Martin

Soubrier³

et al. 2016

J Rheumatol

View full text Add to dashboard Cite

“…In a single-centre, randomised, double-blind, placebo-controlled trial, TCZ use was associated with more complete remission and less frequent relapses 53. In a retrospective multicentre open-label study, 22 patients with GCA with refractory disease and/or with unacceptable side effects due to corticosteroids were treated with TCZ at standard dose of 8 mg/kg/month 54. TCZ use led to rapid and maintained improvement in this group.…”

Section: New Immunosuppressive Agentsmentioning

confidence: 99%

Update on systemic vasculitides

Anwar

Karim

2017

J Clin Pathol

View full text Add to dashboard Cite

Management of systemic vasculitis has been revolutionised over the last decade with the introduction of targeted biological agents. With an increase in both the prevalence and the recognition of vasculitis as well as the high cost of these agents, it is important to ensure their most optimal utilisation. The goals of vasculitis therapy include the induction and maintenance of remissions, preventing relapses, reducing the toxicity of therapy with the aim of reducing morbidity and mortality as well as improving the quality of life of those afflicted. This review focuses on the recent advances in the diagnosis, surveillance and treatment of these conditions.

show abstract

“…Számos kisebb tanulmány és esetriport is hatékonynak találta GCA kezelésében [39][40][41][42][43][44][45][46][47][48].…”

Section: öSszefoglaló Közleményunclassified

Nagyérvasculitisek korszerű kezelése

Szabó

Kiss

2017

Orvosi Hetilap

View full text Add to dashboard Cite

A nagyérvasculitisek közé sorolt óriássejtes arteritisben és Takayasu-arteritisben közös az érfal patogenetikai eltérése, ez alapján felmerül, hogy nem két külön entitásról, hanem egy betegség két megnyilvánulási formájáról van szó. Kezelésükben továbbra is a glükokortikoidé a vezető szerep, szükség esetén cyclophosphamiddal, azatioprinnal, mycofenolat mofetillel kiegészítve. Tekintettel arra, hogy a betegek jelentős része a konvencionális betegségmódosító szerek mellett is szteroiddependens, egyre több klinikai tapasztalat gyűlik a hosszú távú mellékhatások elkerülése ér-dekében adott biológiai terápiás szerek hatékonyságáról. A szerzők célja az új terápiás lehetőségek áttekintése. A tumornekrózis-faktor-alfa-gátlókkal jó terápiás eredmények vannak Takayasu-arteritisben, de óriássejtes arteritisben nem bizonyultak kellően hatékonynak, ugyanakkor az interleukin-6-gátlóval mindkét betegségben szignifikáns javulást sikerült elérni. Az abatacept és az ustekinumab is ígéretesnek tűnik a nagyérvasculitisek kezelésében. Orv. Hetil., 2017, 158(1), 5-12.Kulcsszavak: óriássejtes arteritis, Takayasu-arteritis, tocilizumab, abatacept, ustekinumab Recent advances in the treatment of large vessel vasculitidesGiant cell arteritis and Takayasu arteritis classified to large vessel vasculitides have similar histopathology in the vascular wall proposing that these entities can be different phenotypes on a spectrum of a single disorder. Glucocorticoids are the mainstay of therapy combined with cyclophosphamide, azatioprine and mycofenolate mofetil, when it is required. However, a significant proportion of patients are glucocorticoid-dependent despite of the conventional disease-modifying antirheumatic drugs and suffer from serious side effects of the steroids, therefore alternate options for more effective disease management are needed. The article reviews the advances in the treatment of large vessel vasculitides. Tumor necrosis factor-alpha inhibitors seem to be effective in Takayasu arteritis, but have a little benefit in giant cell arteritis. Interleukin-6 inhibitor appears very promising in both refractory giant cell arteritis and Takayasu arteritis as well. Abatacept and ustekinumab also seem to be a good choice for the therapy. ÖSSZEFOGLALÓ KÖZLEMÉNYRövidítések BAFF = (B-cell activating factor) B-sejt-aktiváló faktor; CTLA-4 = (cytotoxic T-lymphocyte-associated protein 4) citotoxikus Tlymphocyta-asszociált fehérje-4; CYC = cyclophosphamid; DMARD = (disease-modifying antirheumatic drug) betegség-módosító antireumatikus szer; GC = glükokortikoid; GCA = (giant cell arteritis) óriássejtes arteritis; HLA = humán leukocyta-antigén; ICAM-1 = (intercellular cell adhesion molecule-1) intercelluláris sejtadhéziós molekula-1; IFN-γ = interferon-γ; IL = interleukin; ISU = immunszuppresszív; LVV = (large vessel vasculitis) nagyérvasculitis; MTX = methotrexat; PDGF = (platelet-derived growth factor) thrombocytaeredetű növeke-dési faktor; ROCK = (rho kinase) rho-kináz; TA = Takayasuarteritis; TCZ = tocilizumab; TGF-β = (transforming grow...

show abstract

Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

Cited by 117 publications

References 47 publications

Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study

Rapid and Sustained Response to Tocilizumab in Patients with Polymyalgia Rheumatica Resistant or Intolerant to Glucocorticoids: A Multicenter Open-label Study

Update on systemic vasculitides

Nagyérvasculitisek korszerű kezelése

Contact Info

Product

Resources

About